Document Server@UHasselt >
Research >
Research publications >

Please use this identifier to cite or link to this item: http://hdl.handle.net/1942/24073

Title: Design of two phase III open-label trials evaluating ocrelizumab in patients with relapsing-remitting multiple sclerosis and suboptimal response to disease-modifying treatment
Authors: Bermel, R.
Comi, G.
Eralinna, J. -P.
Leist, T. P.
Nicholas, R.
Oreja-Guevara, C.
Siva, A.
Van Wijmeersch, Bart
Wiendl, H.
Bernasconi, C.
Buffels, R.
Csoboth, C.
Han, J.
Musch, B.
Vermersch, P.
Issue Date: 2016
Citation: MULTIPLE SCLEROSIS JOURNAL, 22, p. 615-616 (Art N° P1180)
Notes: [Bermel, R.] Cleveland Clin, Mellen Ctr MS, Cleveland, OH 44106 USA. [Comi, G.] Univ Vita Salute San Raffaele, Milan, Italy. [Eralinna, J. -P.] NEO Res, Turku, Finland. [Leist, T. P.] Thomas Jefferson Univ, Philadelphia, PA 19107 USA. [Nicholas, R.] Imperial Coll Healthcare NHS Trust, London, England. [Nicholas, R.] Imperial Coll, London, England. [Oreja-Guevara, C.] Hosp Clin San Carlos, Madrid, Spain. [Siva, A.] Istanbul Univ, Cerrahpasa Sch Med, Cerrahpasa, Turkey. [Van Wijmeersch, B.] Univ Hasselt, Hasselt, Belgium. [Van Wijmeersch, B.] Rehabil & MS Ctr Overpelt, Hasselt, Belgium. [Wiendl, H.] Univ Munster, Munster, Germany. [Bernasconi, C.; Buffels, R.] F Hoffmann La Roche Ltd, Basel, Switzerland. [Csoboth, C.; Han, J.; Musch, B.] Genentech Inc, San Francisco, CA 94080 USA. [Vermersch, P.] Ctr Hosp Reg Univ Lille, Lille, France.
URI: http://hdl.handle.net/1942/24073
Link to publication: https://onlinelibrary.ectrims-congress.eu/ectrims/2016/32nd/145863/robert.bermel.design.of.two.phase.iii.open-label.trials.evaluating.ocrelizumab.html?f=p6m3e1031o14005
ISI #: 000383267202379
ISSN: 1352-4585
Category: M
Type: Journal Contribution
Appears in Collections: Research publications

Files in This Item:

Description SizeFormat
N/A261.39 kBAdobe PDF

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.